FDA Approves First Gene Therapy for Severe LAD-I

Last updated: 2026-04-01

The U.S. Food and Drug Administration has approved Kresladi (marnetegragene autotemcel), marking a historic milestone as the first gene therapy indicated for the treatment of severe Leukocyte Adhesion Deficiency Type I (LAD-I). This approval, announced via the FDA's official press release, is not merely a scientific achievement — it carries profound regulatory, manufacturing, and strategic implications for any organization operating in the gene therapy or Advanced Therapy Medicinal Products (ATMP) space.

Whether you are a sponsor navigating a BLA for a novel cell or gene therapy, a contract development and manufacturing organization (CDMO) scaling autologous manufacturing processes, or a quality systems professional trying to understand what "first-of-kind" approvals signal about FDA expectations, this approval deserves your close attention.

What Is Leukocyte Adhesion Deficiency Type I?

Leukocyte Adhesion Deficiency Type I (LAD-I) is a rare, life-threatening primary immunodeficiency caused by mutations in the ITGB2 gene, which encodes the CD18 protein — a critical component of beta-2 integrins on the surface of white blood cells. Without functional CD18, neutrophils and other leukocytes cannot adhere to vascular endothelium and migrate to sites of infection, leaving patients virtually defenseless against bacterial and fungal pathogens.

Severe LAD-I is associated with a mortality rate exceeding 60% within the first two years of life without definitive treatment, according to data published in peer-reviewed immunology literature. Prior to this approval, allogeneic hematopoietic stem cell transplantation (HSCT) was the only potentially curative option — a path fraught with risks including graft-versus-host disease (GvHD) and donor availability constraints, particularly in pediatric patients.

The patient population is extremely small. LAD-I affects an estimated 1 in 100,000 to 1 in 500,000 live births globally, classifying it firmly as an ultra-rare disease. This rarity shaped nearly every dimension of the regulatory review pathway for Kresladi.

What Is Kresladi (Marnetegragene Autotemcel)?

Kresladi is an autologous ex vivo lentiviral vector-based gene therapy. The manufacturing process involves:

1. Collection of the patient's own hematopoietic stem and progenitor cells (HSPCs) via apheresis.
2. Transduction of those cells ex vivo using a lentiviral vector encoding a functional copy of the ITGB2 gene.
3. Reinfusion of the gene-corrected cells back into the patient following myeloablative conditioning.

Because the therapy uses the patient's own cells, it eliminates the immunological mismatch risks inherent in allogeneic HSCT — a major clinical and regulatory differentiator. This autologous, one-time treatment model is increasingly the paradigm FDA expects sponsors to justify scientifically and operationally in BLA submissions for rare disease gene therapies.

The Regulatory Pathway: What Made This Approval Possible?

Understanding how Kresladi reached approval is as instructive as knowing what was approved. FDA employed multiple expedited programs, each of which carries distinct obligations sponsors and their regulatory affairs teams must manage proactively.

Breakthrough Therapy Designation

Kresladi received Breakthrough Therapy Designation (BTD), which triggers intensive FDA guidance during development, including more frequent meetings, rolling review eligibility, and senior FDA staff involvement. BTD does not lower the evidentiary bar — it accelerates the organizational pathway to meeting that bar. For sponsors, this means you must be prepared to engage FDA substantively and frequently; organizational unpreparedness at the BTD stage is one of the most common avoidable mistakes I see at Certify Consulting.

Accelerated Approval

The FDA granted Accelerated Approval, meaning the primary endpoint was a surrogate endpoint reasonably likely to predict clinical benefit — specifically, restoration of CD18 expression on neutrophils above a validated threshold. Post-marketing confirmatory trials are now a binding commitment for the sponsor, not an optional aspiration. Failure to complete these trials on schedule can result in withdrawal of approval under the expedited withdrawal procedures established by the Omnibus Appropriations Act of 2023.

Priority Review and Orphan Drug Designation

Kresladi also carried Priority Review (6-month review clock vs. standard 10-month) and Orphan Drug Designation (ODD), conferring seven years of market exclusivity, a 50% tax credit on qualified clinical testing expenses, and waiver of the Prescription Drug User Fee Act (PDUFA) application fee — a fee that exceeded $4 million for FY2024. For sponsors of ultra-rare disease therapies, these financial instruments are not academic; they are central to business viability.

Manufacturing and CMC Implications: The Hardest Part of Gene Therapy Approval

From a regulatory consulting standpoint, the approval of Kresladi underscores a truth I communicate to every gene therapy client: Chemistry, Manufacturing, and Controls (CMC) is where the majority of gene therapy BLAs face their most serious deficiencies.

Autologous Manufacturing Complexity

Autologous therapies present a fundamental CMC challenge — the patient is the donor, the product lot size is one, and the release specifications must account for inter-patient biological variability that has no parallel in conventional biologics. FDA's guidance documents, particularly the 2020 Chemistry, Manufacturing, and Control (CMC) Information for Human Gene Therapy Investigational New Drug Applications (INDs), outline FDA's expectations, but those expectations have evolved significantly with each major approval.

Key CMC Lessons From the Kresladi Approval

FDA's expectation for long-term follow-up of gene therapy patients — up to 15 years post-infusion — is one of the most operationally intensive post-market obligations in all of pharmaceutical regulation. Sponsors who treat this as a post-launch problem rather than a pre-BLA design requirement routinely find themselves out of compliance within 18 months of approval.

What This Approval Signals for the Broader Gene Therapy Landscape

The Kresladi approval is the latest data point in a rapidly maturing regulatory ecosystem for gene and cell therapies. Here is what I believe it signals:

1. FDA Is Comfortable With Lentiviral Vectors at Commercial Scale — With Conditions

Early-generation lentiviral vector programs faced intense scrutiny around insertional oncogenesis risk, rooted in adverse events from early ADA-SCID trials using gammaretroviral vectors. Lentiviral vectors, with their preference for transcriptionally active chromatin and self-inactivating (SIN) designs, have accumulated a substantially improved safety profile, and Kresladi's approval reflects FDA's evolving comfort with this modality — provided sponsors submit robust genotoxicity and clonal tracking data.

2. Surrogate Endpoints Are Viable in Ultra-Rare Diseases — But Post-Market Commitments Are Non-Negotiable

Accelerated Approval using surrogate endpoints is not a shortcut; it is a contract with FDA. As of 2024, FDA has pursued withdrawal proceedings against multiple oncology products that failed to complete confirmatory trials, and the agency has made clear this enforcement posture applies equally to gene therapies.

3. The REMS Question Is Always on the Table

Kresladi's approval does not appear to carry a Risk Evaluation and Mitigation Strategy (REMS) requirement, which is notable given the intensity of the conditioning regimen patients undergo prior to infusion. This reflects the severity of the underlying disease — the risk-benefit calculus at the individual patient level is unambiguous. However, sponsors of gene therapies targeting less severe indications should anticipate REMS scrutiny, particularly around elements to assure safe use (ETASU) at authorized treatment centers.

4. Authorized Treatment Center (ATC) Models Are Becoming Standard for ATMPs

The commercial model for autologous gene therapies like Kresladi invariably involves a restricted network of Authorized Treatment Centers — specialized academic medical centers or hospitals with the infrastructure, expertise, and regulatory authorization to administer the therapy. Sponsors must build ATC qualification programs into their pre-commercial strategy, not bolt them on post-approval. This includes site training, chain-of-identity systems, and pharmacovigilance infrastructure.

Business Implications: What Should Your Organization Be Doing Now?

If you are operating in or adjacent to the gene therapy space, the Kresladi approval should prompt a strategic review across several functions:

Regulatory Affairs

• Review your BLA or IND to ensure your CMC package reflects current FDA expectations for autologous HSPC therapies, as signaled by Kresladi and prior approvals (e.g., Zynteglo, Skysona).
• Assess whether your post-market commitment schedule for any Accelerated Approval product is realistic and adequately resourced.

Quality Systems

• Confirm your chain-of-identity SOPs are validated end-to-end — from patient apheresis collection through reinfusion. FDA has cited chain-of-identity failures as a critical deficiency in gene therapy BLA inspections.
• Evaluate your deviation management system for its ability to handle patient-specific lot failures, including the patient notification and clinical decision-making protocols that must accompany such events.

Manufacturing / CDMO Partners

• If you are a CDMO producing autologous therapies, audit your scheduling systems against commercial demand projections. One of the most persistent post-approval failures in the autologous ATMP space is the inability to scale throughput without compromising quality system integrity.

Pharmacovigilance

• Ensure your adverse event collection infrastructure can support 15-year long-term follow-up. Consider whether your current safety database and patient registry systems are fit for this purpose.

Expert Commentary: Why First-in-Class Approvals Set Precedents You Cannot Ignore

One of the most important — and most underappreciated — aspects of a first-in-class approval like Kresladi is the precedent-setting effect on FDA's internal expectations. When FDA reviewers and inspectors evaluate future lentiviral HSPC gene therapy submissions, they will benchmark those submissions against what was approved for Kresladi. Release specifications, validation packages, clinical monitoring intervals, post-market commitment timelines — all of these will be implicitly shaped by what FDA accepted here.

I have seen sponsors lose months of review time and accumulate costly Complete Response Letters (CRLs) simply because they were unaware of the precedents set by prior approvals in their therapeutic category. Competitive intelligence in regulatory affairs is not about copying your competitors' programs — it is about understanding what FDA has already told the industry it will accept.

At Certify Consulting, with more than 200 clients served and a 100% first-time audit pass rate across eight-plus years of practice, our approach to gene therapy regulatory strategy always begins with a thorough review of publicly available approval packages, inspection databases, and FDA guidance to map the current expectation landscape before a single section of a BLA is drafted.

How Certify Consulting Can Help

Whether you are: - Preparing an IND or BLA for a gene therapy product, - Responding to a Complete Response Letter with CMC deficiencies, - Building a quality system for autologous cell or gene therapy manufacturing, - Navigating post-market commitments under Accelerated Approval, or - Qualifying an Authorized Treatment Center network for a commercial launch,

Certify Consulting provides the expertise and the track record to move your program forward efficiently and compliantly. Visit certify.consulting to learn more or schedule a consultation with Jared Clark directly.

For more on FDA regulatory strategy for biologics and advanced therapies, explore our resources on FDA regulatory consulting for biologics and gene therapies and our guidance on navigating FDA's expedited approval programs.

Frequently Asked Questions

What is Kresladi and what was it approved for?

Kresladi (marnetegragene autotemcel) is an autologous ex vivo lentiviral vector-based gene therapy approved by the FDA as the first treatment of its kind for severe Leukocyte Adhesion Deficiency Type I (LAD-I), a rare and life-threatening primary immunodeficiency.

What regulatory pathway did Kresladi use for FDA approval?

Kresladi received Breakthrough Therapy Designation, Accelerated Approval (based on a surrogate endpoint), Priority Review, and Orphan Drug Designation — a combination of expedited pathways that reflects both the severity of LAD-I and the unmet medical need in this patient population.

What are the post-market obligations for Kresladi's sponsor under Accelerated Approval?

Under Accelerated Approval, the sponsor is required to conduct confirmatory clinical trials demonstrating actual clinical benefit. Failure to complete these trials on schedule can result in expedited withdrawal of approval. Additionally, FDA gene therapy guidance requires long-term safety follow-up of up to 15 years post-infusion.

What does the Kresladi approval mean for other gene therapy sponsors?

The approval sets regulatory precedents for CMC standards, release specifications, and post-market requirements for autologous lentiviral HSPC gene therapies. Sponsors developing similar modalities should treat the Kresladi approval package as a benchmark when designing their own regulatory strategies.

How does autologous gene therapy manufacturing differ from traditional biologics manufacturing?

Autologous gene therapies use the patient's own cells as starting material, meaning each lot is unique to one patient. This creates fundamental differences in batch release, quality control, chain-of-identity management, and scalability compared to allogeneic or traditional biologic manufacturing processes.

Last updated: 2026-04-01

Jared Clark is Principal Consultant at Certify Consulting, a FDA regulatory consulting firm. He holds credentials as JD, MBA, PMP, CMQ-OE, CPGP, CFSQA, and RAC. Certify Consulting has served 200+ clients with a 100% first-time audit pass rate. Learn more at certify.consulting.